What Happened?
Shares of medical device company Integra LifeSciences (NASDAQ: IART) jumped 13.6% in the afternoon session after the company reported strong fourth quarter 2024 results that beat analysts' EPS and EBITDA expectations.
On the other hand, its full-year revenue and EPS guidance fell short of Wall Street's estimates. The company expects continued demand for its portfolio but flagged potential headwinds, including intermittent product shipping holds. Overall, while this was a strong quarter with solid execution, cautious guidance suggests near-term uncertainty.
Is now the time to buy Integra LifeSciences? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Integra LifeSciences’s shares are quite volatile and have had 16 moves greater than 5% over the last year. But moves this big are rare even for Integra LifeSciences and indicate this news significantly impacted the market’s perception of the business.
Integra LifeSciences is up 9% since the beginning of the year, but at $25.09 per share, it is still trading 43.3% below its 52-week high of $44.27 from February 2024. Investors who bought $1,000 worth of Integra LifeSciences’s shares 5 years ago would now be looking at an investment worth $443.84.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
